# A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

> **NCT06952478** · PHASE3 · RECRUITING · sponsor: **Celltrion** · enrollment: 486 (estimated)

## Conditions studied

- Refractory or Relapsed Multiple Myeloma

## Interventions

- **BIOLOGICAL:** CT-P44(Daratumumab)
- **BIOLOGICAL:** Darzalex Faspro(Daratumumab)

## Key facts

- **NCT ID:** NCT06952478
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-12
- **Primary completion:** 2027-11-15
- **Final completion:** 2029-06-25
- **Target enrollment:** 486 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06952478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06952478, "A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06952478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*